URL has been copied successfully!
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
Two years ago, Mohit Gupta, an analyst who works for Adar1 Capital’s Dan Schneeberger, walked into Schneeberger’s Austin, Texas, office and pitched an idea to build from the ground up a new company to develop a better, long-acting antibody treatment for atopic dermatitis.
Schneeberger’s day job, of course, is to invest in biotech companies that are already developing drugs, not start one on his own.
Please follow us:
